Quantification of N, N’ N’’-triethylenethiophosphoramide, N, N’ N’’-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies

Huang, Liusheng; Winger, Beth Apsel; Cheah, Vincent; Gingrich, David; Marzan, Florence; Lü, Ying; Cooper, Jennifer C; Aweeka, Francesca; Long‐Boyle, Janel

doi:10.1016/j.jcoa.2022.100054

Cited by 4 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study including two neonates demonstrated that the comparison of calculated gentamicin concentration from VAMS to observed plasma concentration met the acceptance criteria of an incurred sample reanalysis test (≤20%) and results were obtained promptly 101 . Other LC‐MS/MS assays that have been recently developed include assays for the quantification of thiotepa, its metabolite tepa, CP and its metabolite 4OHCP in 10 µL liquid plasma samples and furosemide in 10 µL VAMS samples 102,103 …”

Section: Applicationsmentioning

confidence: 97%

“…101 Other LC-MS/MS assays that have been recently developed include assays for the quantification of thiotepa, its metabolite tepa, CP and its metabolite 4OHCP in 10 µL liquid plasma samples and furosemide in 10 µL VAMS samples. 102,103 As a part of clinical bridging studies, several studies have compared two or more microsampling approaches for a given neonatal or paediatric application. For the analysis of meropenem, a capillary with lithium heparin anticoagulant was found to perform better than the MSW, although both yielded acceptable concentrations comparable to those obtained from conventional arterial catheter sampling.…”

Section: Neonatal and Paediatric Studiesmentioning

confidence: 99%

“… 101 Other LC‐MS/MS assays that have been recently developed include assays for the quantification of thiotepa, its metabolite tepa, CP and its metabolite 4OHCP in 10 µL liquid plasma samples and furosemide in 10 µL VAMS samples. 102 , 103 …”

Section: Applicationsmentioning

confidence: 99%

See 2 more Smart Citations

Blood microsampling technologies: Innovations and applications in 2022

Thangavelu

Wouters

Kindt

et al. 2023

Analytical Science Advances

View full text Add to dashboard Cite

With the development of highly sensitive bioanalytical techniques, the volume of samples necessary for accurate analysis has reduced. Microsampling, the process of obtaining small amounts of blood, has thus gained popularity as it offers minimal‐invasiveness, reduced logistical costs and biohazard risks while simultaneously showing increased sample stability and a potential for the decentralization of the approach and at‐home self‐sampling. Although the benefits of microsampling have been recognised, its adoption in clinical practice has been slow. Several microsampling technologies and devices are currently available and employed in research studies for various biomedical applications. This review provides an overview of the state‐of‐the‐art in microsampling technology with a focus on the latest developments and advancements in the field of microsampling. Research published in the year 2022, including studies (i) developing strategies for the quantitation of analytes in microsamples and (ii) bridging and comparing the interchangeability between matrices and choice of technology for a given application, is reviewed to assess the advantages, challenges and limitations of the current state of microsampling. Successful implementation of microsampling in routine clinical care requires continued efforts for standardization and harmonization. Microsampling has been shown to facilitate data‐rich studies and a patient‐centric approach to healthcare and is foreseen to play a central role in the future digital revolution of healthcare through continuous monitoring to improve the quality of life.

show abstract

Section: Applicationsmentioning

confidence: 97%

Section: Neonatal and Paediatric Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Blood microsampling technologies: Innovations and applications in 2022

Thangavelu

Wouters

Kindt

et al. 2023

Analytical Science Advances

View full text Add to dashboard Cite

show abstract

“…P larly, it is a prodrug primarily metabolized by the hepatic CYP2B6, CYP2C9 and C enzymes to its main metabolite 4-hydroxycyclophosphamide, which interconvert its tautomer aldophosphamide, and is spontaneously transformed into the active responsible for alkylation, the phosphoramide mustard. This compound is ionize physiological pH and cannot enter the cell, unlike 4-hydroxycyclophosphamide, can easily diffuse into cells, leading to the plasma concentration responsible for the peutic effect [60]. Triclocarban (TCC, Figure 7) is a ubiquitous antimicrobial agent found in con and personal care products [61,62].…”

Section: Cyclophosphamidementioning

confidence: 99%

Impact of Cytochrome P450 Enzymes on the Phase I Metabolism of Drugs

et al. 2023

View full text Add to dashboard Cite

The cytochrome P450 (CYP) enzyme family is the major enzyme system catalyzing the phase I metabolism of xenobiotics, including pharmaceuticals and toxic compounds in the environment. A major part of the CYP-dependent xenobiotic metabolism is due to polymorphic and inducible enzymes, which may, quantitatively or qualitatively, alter or enhance drug metabolism and toxicity. Drug–drug interactions are major mechanisms caused by the inhibition and/or induction of CYP enzymes. Particularly, CYP monooxygenases catalyze hydroxylation reactions to form hydroxylated metabolites. The secondary metabolites are sometimes as active as the parent compound, or even more active. The aim of this review is to summarize some of the significative examples of common drugs used for the treatment of diverse diseases and underline the activity and/or toxicity of their metabolites.

show abstract